JPS61233694A - Growth factor contained in bovine spleen and method of isolating same - Google Patents
Growth factor contained in bovine spleen and method of isolating sameInfo
- Publication number
- JPS61233694A JPS61233694A JP60073829A JP7382985A JPS61233694A JP S61233694 A JPS61233694 A JP S61233694A JP 60073829 A JP60073829 A JP 60073829A JP 7382985 A JP7382985 A JP 7382985A JP S61233694 A JPS61233694 A JP S61233694A
- Authority
- JP
- Japan
- Prior art keywords
- growth factor
- solution
- bovine spleen
- salt
- bovine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明はウシ脾臓中に含まれる成長因子及びその単離方
法に関する。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to growth factors contained in bovine spleen and a method for isolating the same.
従来の技術
多くの動物細胞は、細胞培養の技術をもって継代され、
そのうちのいくつかの系、特にヒト由来のいくつかの系
は有用物質の産生手段として広く応用されようとしてい
る。モノクローン抗体やリンホカインをリンパ球系の細
胞に、インターフェロンを線維芽細胞に生産させようと
することが例としてあげられる。これらの細胞の培養に
は多くの場合、ウシ胎児血清やウシ新生児血清等の血清
の培地への添加が不可欠とされている。Conventional technology Many animal cells are passaged using cell culture techniques.
Some of these systems, especially those derived from humans, are about to be widely applied as means for producing useful substances. Examples include trying to make monoclonal antibodies and lymphokines be produced by lymphoid cells, and interferon by fibroblasts. In many cases, the addition of serum such as fetal bovine serum or newborn bovine serum to the culture medium is essential for culturing these cells.
発明が解決しようとしている問題点
しかし、その培養及び有用物質の産生、抽出、精製には
種々の制約があることも事実である。極めて多くの細胞
が血清の存在下でしか生存あるいは増殖し得ないのはそ
の最も大きな制約の一つである。又、この血清という、
組成が完全には明らかとなっていない蛋白質の混合物が
培地中に含まれることによシ、有用物質の単離、精製が
著しく困難になることもある。Problems to be Solved by the Invention However, it is also true that there are various restrictions on the cultivation, production, extraction, and purification of useful substances. One of its biggest limitations is that a large number of cells can survive or proliferate only in the presence of serum. Also, this serum is called
Isolation and purification of useful substances may become extremely difficult due to the presence in the culture medium of a mixture of proteins whose composition is not completely clear.
近年、無血清培地あるいは合成培地の研究が盛んになっ
たのは、これらの理由5を出発点としているといっても
過言ではない。しかし、これらの研究も大きな壁につき
あたっている。その理由の最も大きなものとして、血清
中に存在する成長因子が不明であることがあげられる。It is no exaggeration to say that research on serum-free media or synthetic media has become active in recent years, starting from these reasons 5. However, these studies have also hit a major wall. The biggest reason for this is that the growth factors present in serum are unknown.
つまり、血清中にどのような成長因子がどのように存在
するかが明らかとなっていない。ここに種々の成長因子
を研究する価値がある。すなわち、種々の細胞に対する
成長因子を発見し、単離、精製することが、血清添加培
地に代わりうる無血清培地あるいは合成培地の研究に不
可欠なステップといえる。現在までのところ、米国特許
第3948875号に示されている上皮細胞成長因子(
Epidermal GrowthFactor; E
GF )、米国特許第4979896号に示されている
血小板由来成長因子(PlateletDerived
Growth Factor ; P DGF )
等が発見され、単離されている。このうち上皮細胞成長
因子は有効濃度が数十ng/mlとかなり高い濃度が必
要であるし、血小板由来成長因子は数n g /mlで
効果を発現するが、原料の制約があることや、収量に問
題が残っている。近年Gospodarowiczら(
Proceedings of the Nation
al Academyof 5cience、第81
巻6963〜6967ページ)やLobbら(B io
chemi st ry 、第23巻、6295〜62
99ページ)によってウシ脳やウシ脳下垂体を出発原料
としてほぼ純品といえる線維芽細胞生長因子(Fibl
oblast Growth Factori FGF
)が単離され、有効濃度も数+pg/nl〜数n g
/yslと極めて低濃度であることが示された。In other words, it is not clear what kind of growth factors are present in serum. Here it is worth studying various growth factors. In other words, discovering, isolating, and purifying growth factors for various cells can be said to be an essential step in researching serum-free or synthetic media that can replace serum-supplemented media. To date, epidermal growth factor (
Epidermal Growth Factor; E
GF ), platelet derived growth factor (PlateletDerived) shown in U.S. Patent No. 4,979,896
Growth Factor; PDGF)
etc. have been discovered and isolated. Among these, epithelial cell growth factor requires a fairly high effective concentration of several tens of ng/ml, and platelet-derived growth factor is effective at a few ng/ml, but there are restrictions on raw materials, Yield remains a problem. Recently, Gospodarowicz et al.
Proceedings of the Nation
al Academy of 5science, 81st
Volume 6963-6967) and Lobb et al.
Chemistry, Volume 23, 6295-62
Fibroblast growth factor (Fibl
oblast Growth Factory FGF
) was isolated, and the effective concentration ranged from several + pg/nl to several n g
It was shown that the concentration was extremely low./ysl.
しかし、両者の報告によると、大量の入手が容易なウシ
脳1即から得られる線紐芽細胞生長因子はせいぜい50
ngであり、大量の入手がむずかしいウシ脳下垂体1
即からでも200ng程度の線維芽細胞成長因子しか得
られない。However, according to both reports, the fimbriae cell growth factor obtained from bovine brain, which is easily available in large quantities, is at most 50%.
Bovine pituitary gland 1, which is NG and difficult to obtain in large quantities
Only about 200 ng of fibroblast growth factor can be obtained immediately.
問題点を解決するための手段
Gospodarowiczらの単離したウシ脳あるい
はウシ脳下垂体から単離された線維芽細胞成長因子と同
様の活性を持つ成長因子が大量に得られれば、無血清培
地や合成培地の研究に大きく寄与することは間違いない
。本発明者らは従来よυ線維芽細胞成長因子に注目し、
鋭意研究を重ね次結果、原料として大量入手が容易なウ
シ脾臓中に該成長因子活性が含まれることを見出し、こ
れを単離するととができた。Means to Solve the Problem If a large amount of growth factor with the same activity as the fibroblast growth factor isolated from bovine brain or bovine pituitary gland, which was isolated by Gospodarowicz et al., could be obtained, serum-free medium or There is no doubt that this will greatly contribute to research on synthetic media. The present inventors have conventionally focused on υ fibroblast growth factor,
After extensive research, they discovered that the growth factor activity was contained in bovine spleen, which is easily available in large quantities as a raw material, and were able to isolate it.
ウシ脾臓を塩類溶液とともに破砕し、抽出上清を得て、
これを弱酸性陽イオン交換体で処理して成長因子を含む
粗両分をとる。これを更にヘパリン固定化セファロース
で処理することによって目的とする成長因子を単離する
。Crush the bovine spleen with a saline solution to obtain the extracted supernatant,
This is treated with a weakly acidic cation exchanger to obtain a crude fraction containing growth factors. This is further treated with heparin-immobilized Sepharose to isolate the desired growth factor.
本発明の特徴は、ウシ脾臓抽出液から成長因子を単離す
ることにある。すなわち、ウシ脾臓抽出液はそのままで
は細胞の培養には成長因子の他に強力な成長阻害因子が
含まれるので、そのままでは使用できない。前述したよ
うにウシ脾臓を塩類溶液(塩化ナトリウム、硫酸アンモ
ニウム等で電気休導度が約1.5 m 8又はそれ以下
のもの)中で破砕し、遠心分離等によって抽出液を得、
この抽出液を硫酸アンモニウム30%飽和−75%飽和
で塩析する。得られた沈殿を0.1Mリン酸ナトリウム
緩衝液、pH6,0に対して十分に透析した後、同緩衝
液で平衡化した弱酸性陽イオン交換体(例えばCM−セ
ファデックスC−50、CM−52等)に接触させて成
長因子を吸着させた後、同交換体を平衡化に用いた緩衝
液及び0.15M塩化ナトリウムを含む0.1Mリン酸
ナトリウム、pH6゜0で洗浄し、0.6M塩化ナトリ
ウムを含む0.1Mリン酸す) IJウム緩衝液、pH
6,0で成長因子を含む両分を溶出させる。得られた成
長因子含有画分を0.6M塩化ナトリウムを含む0.0
1Mリン酸ナトリウム緩衝液、pH7,0で平衡化した
ヘパリン固定化セファロースに接触させて成長因子を吸
着させ、同樹脂を平衡化に用いた緩衝液及び1.0M塩
化ナトリウムを含む0.01Mリン酸ナトリウム、pH
7,0で洗浄した後、塩化す) IJウムの濃度を上げ
た緩衝液を用いると成長因子が単離されてくる。A feature of the present invention is the isolation of growth factors from bovine spleen extract. That is, bovine spleen extract cannot be used as it is because it contains strong growth inhibitory factors in addition to growth factors when culturing cells. As mentioned above, the bovine spleen is crushed in a saline solution (sodium chloride, ammonium sulfate, etc. with an electrical rest conductivity of about 1.5 m 8 or less), and an extract is obtained by centrifugation or the like.
This extract is salted out with ammonium sulfate 30%-75% saturated. The resulting precipitate was thoroughly dialyzed against 0.1 M sodium phosphate buffer, pH 6.0, and then diluted with a weakly acidic cation exchanger (e.g. CM-Sephadex C-50, CM -52, etc.) to adsorb the growth factors, the exchanger was washed with the buffer used for equilibration and 0.1M sodium phosphate, pH 6.0, containing 0.15M sodium chloride. 0.1M phosphoric acid containing 6M sodium chloride) IJum buffer, pH
Both fractions containing growth factors are eluted at 6.0. The obtained growth factor-containing fraction was diluted with 0.0
The growth factors were adsorbed by contacting with heparin-immobilized Sepharose equilibrated with 1M sodium phosphate buffer, pH 7.0, and the same resin was mixed with the buffer used for equilibration and 0.01M phosphate containing 1.0M sodium chloride. sodium acid, pH
After washing with 7.0 and chloride), the growth factor can be isolated by using a buffer solution with increased concentration of IJium.
この単離工程において硫酸アンモニウムによる塩析及び
それに続く透析の工程は、どちらか一方又は両方とも省
略しても、得られる成長因子に本質的な違いは生じない
。しかし、弱酸性陽イオン交換体処理及びヘパリン固定
化セファロース処理は不可欠である。In this isolation step, one or both of the steps of salting out with ammonium sulfate and subsequent dialysis may be omitted without causing any essential difference in the obtained growth factor. However, treatment with a weakly acidic cation exchanger and treatment with heparin-immobilized Sepharose is essential.
こうして得られた成長因子は8D8−ポリアクリルアミ
ドゲル電気泳動法による分子量測定で約16.000〜
18,000の分子量を、アンホラインを用いた等電点
電気泳動法で9.5〜10,5の等電点を示した。成長
因子活性をウシ胎児心臓内皮細胞(Fetal Bov
ine Hea、t EndothelialCell
、ATCC,CRL−1395)を用いた細胞増殖促進
活性測定及びマウス3T3細胞を用いた3H−チミジン
取り込み活性の測定において数十pg/ mlでも促進
効果を示した。The molecular weight of the growth factor thus obtained was determined by 8D8-polyacrylamide gel electrophoresis to be approximately 16.000~
It showed a molecular weight of 18,000 and an isoelectric point of 9.5 to 10.5 by isoelectric focusing using ampholine. Growth factor activity was determined in bovine fetal heart endothelial cells (Fetal Bov).
ine Hea,t EndothelialCell
, ATCC, CRL-1395) and 3H-thymidine uptake activity using mouse 3T3 cells, even tens of pg/ml showed a promoting effect.
発明の効果
成長因子活性を比較すると、前述した上皮細胞増殖因子
の有効濃度が数十ng/ ml 、強い成長因子活性を
もつといわれる血小板由来成長因子の有効濃度が数ng
/meであるのに対し、本発明のウシ脾臓中に含まれる
成長因子は数十pg/ynlでも促進効果を示し極めて
強い活性をもつものであり、今後これを応用する範囲は
かなり広いものと思われる。Effects of the Invention Comparing the growth factor activities, the effective concentration of the above-mentioned epidermal growth factor is several tens of ng/ml, and the effective concentration of platelet-derived growth factor, which is said to have strong growth factor activity, is several ng/ml.
/me, the growth factor contained in the bovine spleen of the present invention exhibits a promoting effect even at a few tens of pg/ynl and has extremely strong activity, and the scope of its application will be quite wide in the future. Seem.
また原料のウシ脾臓が大量に入手しやすい点も、本発明
の利点である。Another advantage of the present invention is that the raw material, bovine spleen, is readily available in large quantities.
実施例
実施例 1
ウシ牌R#4に&を細切し、8tの0.1jM硫酸アン
モニウム水溶液を加えてホモゲナイザーで破砕した。リ
ン酸を加えてI)H4,5に調整した後、遠心分離して
上清を得た。この上清に水酸化ナトリウムを加えてpH
を約7にもどした後、硫酸アンモニウムを加えて30%
飽和とし、遠心分離して沈殿を捨てた。上清に更に硫酸
アンモニウムを加えて75%飽和とした後、遠心分離し
て上清を捨てた。得られた沈殿を水にとかし、0.1M
リン酸す) IJウム緩衝液、pH6,0に対して十分
に透析した。透析後生じた不溶物を遠心分離して除去し
た後、0.1Mリン酸ナトリウム緩衝液、pH6,0で
平衡化したCM−セファデックスC−50を充填したカ
ラム(カラムサイズ3.6X15crn)に通じて成長
因子を吸着させた後、同カラムを平衡化に用いた緩衝液
及び0.15M塩化す) IJウムを含む0.1Mリン
酸ナトリウム緩衝液、I)H6,0で洗浄し、0.6M
塩化ナトリウムを含trO,IMリン酸ナトリウム、p
H6,0で成長因子画分を溶出した。Examples Example 1 Beef tiles R#4 were cut into small pieces, 8 tons of 0.1jM ammonium sulfate aqueous solution was added, and the mixture was crushed using a homogenizer. After adjusting to I) H4,5 by adding phosphoric acid, the mixture was centrifuged to obtain a supernatant. Add sodium hydroxide to this supernatant to adjust the pH.
After returning to about 7, add ammonium sulfate to 30%
The mixture was saturated, centrifuged, and the precipitate was discarded. Ammonium sulfate was further added to the supernatant to achieve 75% saturation, followed by centrifugation and the supernatant was discarded. The obtained precipitate was dissolved in water and diluted with 0.1M
The mixture was thoroughly dialyzed against IJum buffer, pH 6.0. After removing the insoluble substances generated after dialysis by centrifugation, the mixture was transferred to a column (column size 3.6 x 15 crn) packed with CM-Sephadex C-50 equilibrated with 0.1 M sodium phosphate buffer, pH 6.0. After adsorption of the growth factors through the column, the same column was washed with the buffer used for equilibration and 0.1 M sodium phosphate buffer containing 0.15 M sodium chloride, I) H6,0, .6M
Contains sodium chloride trO, IM sodium phosphate, p
The growth factor fraction was eluted with H6,0.
得られた画分を0.6M塩化す) IJウムを含む0.
01Mリン酸ナトリウム緩衝液、p)(7,oで平衡化
したヘパリン固定化セファロースを充填したカラム(カ
ラムサイズ1.2X10crn)に通じて成長因子を吸
着させ、同カラムを平衡化に用いた緩衝液及び1.0M
塩化ナトリウムを含む0.01Mリン酸す) IJウム
緩衝液、pH7,0で洗浄した後、0.01Mリン酸ナ
トリウム緩衝液、pH7,0を基本とする1、0Mから
2.0Mまでの塩化ナトリウムの直線濃度勾配溶出法で
成長因子を溶出した。成長因子は塩化ナトリウム濃度1
.5M付近に溶出された。The obtained fraction was 0.6M chloride) containing 0.6M chloride.
Growth factors were adsorbed through a column (column size 1.2X10 crn) packed with heparin-immobilized Sepharose equilibrated with 01M sodium phosphate buffer, p) (7,0), and the same column was packed with the buffer used for equilibration. liquid and 1.0M
After washing with IJum buffer, pH 7.0 (0.01M phosphoric acid containing sodium chloride), chloride from 1.0M to 2.0M based on 0.01M sodium phosphate buffer, pH 7.0. Growth factors were eluted using a linear sodium gradient elution method. The growth factor is sodium chloride concentration 1
.. It was eluted around 5M.
この方法によって得られた成長因子は8DS−ポリアク
リルアミドゲル電気泳動法で分子量約17、000のと
ころに単一の蛋白質のバンドが検出されるのみであった
。成長因子活性をウシ胎児心臓内皮細胞(Fetal
Bovine Heart Endothelial
Ce1lXATCC,CRL −1395)を用いた細
胞増殖促進活性で測定したところ表−1に示す結果を得
た。In the growth factor obtained by this method, only a single protein band was detected at a molecular weight of about 17,000 by 8DS-polyacrylamide gel electrophoresis. Growth factor activity was determined in bovine fetal heart endothelial cells (Fetal
Bovine Heart Endothelial
When the cell proliferation promoting activity was measured using CellXATCC, CRL-1395), the results shown in Table 1 were obtained.
表−1
0・1 34
0.3 44
1.0 74
3.0 110
植込み細胞数 ; 5 X 104/dish実施例
2
実施例1に従って精製を進め、最終工程の塩濃度勾配溶
出法を、2.0M塩化ナトリウムを用いた段階的溶出法
にかえて成長因子を溶出させた。得られた画分を5D8
−ポリアクリルアミドゲル電気泳動法で分析したところ
、数本の極微量の混在物のバンドが認められた以郊は実
施例1と同様の結果を得た。細胞増殖促進活性の測定結
果も実施例1と同様であった。Table 1 0・1 34 0.3 44 1.0 74 3.0 110 Number of implanted cells; 5 Growth factors were eluted using a stepwise elution method using .0M sodium chloride. The obtained fraction was 5D8
- When analyzed by polyacrylamide gel electrophoresis, the same results as in Example 1 were obtained, except that a few bands of extremely small amounts of inclusions were observed. The measurement results of cell proliferation promoting activity were also the same as in Example 1.
実施例 3
実施例1に従って硫酸アンモニウム30%〜75%飽和
沈殿を得た後、沈殿を水に溶かして電気伝導度を1.5
m 8に調整した後、0.1MIJン酸ナトジナトリ
ウム緩衝液6.0で平衡化したCM−52,150ml
を加え、5°Cで1時間攪拌した。その後、グラスフィ
ルター上で濾過後、同樹脂を平衡化に用いた緩衝液で洗
浄し、直径3.6mのカラムに充填してから更に0.1
5M塩化ナトリウムを含む0.1Mリン酸ナトリウム緩
衝液、pH6,0で洗浄した。0.6M塩化ナトリウム
を含む0.1Mリン酸す) IJウム、pH6,0で成
長因子を含む両分をi出し、得られた画分について実施
例2に示す方法でヘパリン固定化セファロースカラムク
ロマトグラフィーを行って、成長因子を単離した。Example 3 After obtaining a 30% to 75% saturated ammonium sulfate precipitate according to Example 1, the precipitate was dissolved in water to reduce the electrical conductivity to 1.5.
CM-52, 150 ml equilibrated with 0.1 MIJ sodium disodinate buffer 6.0 after adjusting to 8 m
was added and stirred at 5°C for 1 hour. Then, after filtration on a glass filter, the same resin was washed with the buffer used for equilibration, packed into a column with a diameter of 3.6 m, and then
Washed with 0.1M sodium phosphate buffer containing 5M sodium chloride, pH 6.0. 0.1M phosphoric acid (containing 0.6M sodium chloride), IJum, pH 6.0, and both fractions containing growth factors were extracted, and the obtained fractions were subjected to heparin-immobilized Sepharose column chromatography using the method shown in Example 2. Graphography was performed to isolate the growth factors.
8D8−ポリアクリルアミドゲル電気泳動法による分析
、細胞増殖促進活性の測定のいずれも実施例2と同様の
結果を得た。The same results as in Example 2 were obtained in both analysis by 8D8-polyacrylamide gel electrophoresis and measurement of cell proliferation promoting activity.
実施例 4
ウシ脾臓4即を細切し、8tの0.05M塩化ナトリウ
ムを加えてホモゲナイザーで破砕した。実施例1と同様
にして抽出上清を得、との上清に水酸化ナトリウムを加
えてpns、oとした後、0.1Mリン酸ナトリウム、
pH6,0で平衡化したCM−52,1501/を加え
、5°Cで1時間攪拌した。Example 4 Four pieces of bovine spleen were cut into small pieces, 8 tons of 0.05M sodium chloride was added, and the mixture was crushed using a homogenizer. The extraction supernatant was obtained in the same manner as in Example 1, and sodium hydroxide was added to the supernatant to make pns, o, and then 0.1M sodium phosphate,
CM-52,1501/ equilibrated at pH 6.0 was added and stirred at 5°C for 1 hour.
実施例3で示した方法で洗浄後、カラムに充填し、更に
洗浄、溶出を行った。得られた成長因子含有画分を実施
例1に示す方法でヘパリン固定化セファロースカラムク
ロマトグラフィーを行って成長因子を単離した。After washing according to the method shown in Example 3, the column was filled, and further washing and elution were performed. The obtained growth factor-containing fraction was subjected to heparin-immobilized Sepharose column chromatography according to the method shown in Example 1 to isolate growth factors.
8D8−ポリアクリルアミドゲル電気泳動法による分析
、細胞増殖促進活性の測定のいずれも実施例1と同様の
結果を得た。The same results as in Example 1 were obtained in both analysis by 8D8-polyacrylamide gel electrophoresis and measurement of cell proliferation promoting activity.
Claims (2)
子、 (A)分子量約16,000〜18,000(B)等電
点9.5〜10.5 (C)ヘパリン固定化セファロースに強い親和性をもつ
。(1) Growth factor contained in bovine spleen and having the following properties: (A) Molecular weight approximately 16,000-18,000 (B) Isoelectric point 9.5-10.5 (C) Heparin-immobilized Sepharose has a strong affinity for
8,000、等電点9.5〜10.5、ヘパリン固定化
セファロースに対して親和性をもつ成長因子を単離する
過程において、次のステップを含む成長因子の単離方法
、 (a)ウシ脾臓抽出液より弱酸性陽イオン交換体を用い
て部分精製する。 (b)(a)で得られた成長因子含有画分からヘパリン
固定化セファロースを用いて成長因子を単離する。(2) Molecular weight contained in bovine spleen: approximately 16,000 to 1
8,000, an isoelectric point of 9.5 to 10.5, a method for isolating a growth factor comprising the following steps in the process of isolating a growth factor having an affinity for heparin-immobilized sepharose, (a) Partially purified from bovine spleen extract using a weakly acidic cation exchanger. (b) Growth factors are isolated from the growth factor-containing fraction obtained in (a) using heparin-immobilized Sepharose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60073829A JPS61233694A (en) | 1985-04-08 | 1985-04-08 | Growth factor contained in bovine spleen and method of isolating same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60073829A JPS61233694A (en) | 1985-04-08 | 1985-04-08 | Growth factor contained in bovine spleen and method of isolating same |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS61233694A true JPS61233694A (en) | 1986-10-17 |
Family
ID=13529420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60073829A Pending JPS61233694A (en) | 1985-04-08 | 1985-04-08 | Growth factor contained in bovine spleen and method of isolating same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61233694A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535025A (en) * | 1999-06-25 | 2003-11-25 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム | How to induce angiogenesis in micro-organs |
US8142990B2 (en) | 2001-11-05 | 2012-03-27 | Medgenics Inc. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US8501396B2 (en) | 2001-11-05 | 2013-08-06 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8530149B2 (en) | 2001-11-05 | 2013-09-10 | Medgenics Medical Israel Ltd | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8586024B2 (en) | 2006-09-14 | 2013-11-19 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US8685635B2 (en) | 2002-11-05 | 2014-04-01 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
-
1985
- 1985-04-08 JP JP60073829A patent/JPS61233694A/en active Pending
Non-Patent Citations (1)
Title |
---|
PROC.NATL.ACAD.SCI.USA=1984 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535025A (en) * | 1999-06-25 | 2003-11-25 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム | How to induce angiogenesis in micro-organs |
US8142990B2 (en) | 2001-11-05 | 2012-03-27 | Medgenics Inc. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8293463B2 (en) | 2001-11-05 | 2012-10-23 | Medgenics Inc. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US9107896B2 (en) | 2001-11-05 | 2015-08-18 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8501396B2 (en) | 2001-11-05 | 2013-08-06 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8530149B2 (en) | 2001-11-05 | 2013-09-10 | Medgenics Medical Israel Ltd | Dermal micro-organs, methods and apparatuses for producing and using the same |
US9101595B2 (en) | 2002-11-05 | 2015-08-11 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8685635B2 (en) | 2002-11-05 | 2014-04-01 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8771291B2 (en) | 2002-11-05 | 2014-07-08 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US8586024B2 (en) | 2006-09-14 | 2013-11-19 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US8877175B2 (en) | 2006-09-14 | 2014-11-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US9687564B2 (en) | 2006-09-14 | 2017-06-27 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Olsson et al. | Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells | |
US4350687A (en) | Platelet derived cell growth factor | |
Ghosh et al. | Purification and properties of molecular-weight variants of human placental alkaline phosphatase | |
US4465624A (en) | Process for producing erythropoietin | |
RU2596408C2 (en) | Method of purifying human granulocyte-colony stimulating factor from recombinant e.coli | |
KR100234497B1 (en) | Large, latent complexes of tgf-beta2 and tgf-beta3. | |
Baseler et al. | Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses | |
OLSSON et al. | Cationic Proteins of Human Granulocytes: I. Isolation of the Cationic Proteins from the Granules of Leukaemic Myeloid Cells | |
EP0356836B1 (en) | Thrombin-binding substance and process for preparing the same | |
JP2007039454A (en) | Vegetarian protein a preparation and method for forming the same | |
JPS61233694A (en) | Growth factor contained in bovine spleen and method of isolating same | |
US5071961A (en) | Method of enrichment of coagulation factors ii, vii, ix and x | |
Torres et al. | Fractionation of granule proteins of granulocytes by copper chelate chromatography | |
US3925152A (en) | Virus separation | |
HU194584B (en) | Process for preparing protein-type material with antineoplastic effect and monoclonal antibodies specific thereto and bonded to a carrier | |
CA2128215C (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
JPS58192896A (en) | Interferon | |
US4189535A (en) | Serum cell growth promoting materials | |
CN86108955A (en) | New cell growth regulator | |
KR19980703851A (en) | Method for Purifying Glycoproteins such as Erythropoietin | |
EP0529348B1 (en) | Process for the purification of factor XIII, monoclonal antibodies against factor XIIIA, preparation and use thereof | |
JPS61229894A (en) | Growth factor existing in human placenta and separation thereof | |
US4495096A (en) | Process for producing and obtaining anaphylatoxin-and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form | |
WO1991018925A1 (en) | Novel megakaryocyte colony stimulating factor and production thereof | |
US4308204A (en) | Process for preparing the third component of the complement from human blood plasma |